Consensus Amgen Inc. Sao Paulo

Stocks

AMGN34

BRAMGNBDR004

Pharmaceuticals

Delayed Sao Paulo 05:09:56 27/08/26 am AEST			5-day change	1st Jan Change
81.32 ^BRL	-0.05%		-0.15%	+23.29%

01:50am	UK Shares Fall as Global Tensions Mount; AstraZeneca Drops	MT
01:48am	European Stocks Close Mostly Lower in Thursday Trading as Investors Await Fed Chair Speech	MT

Evolution of the Average Target: Amgen Inc.

Evolution of the Target Price: Amgen Inc.

Changes in Analyst Recommendations: Amgen Inc.

e805baad3ffd.S-e7yYcxTDozX3LKG_lT-BGkH8VfIrUoLnNTIXU8ujk.BrP4nv5jA2lyMyu7L6ALsF7xK4AaGsdfFzwxQh5pzgA8qO790Ql6DEUAFQ~4722f7eb1899f8f768fabd9c8b744651

Analysts' recommendations: Amgen Inc.

20/08	Piper Sandler Adjusts Price Target on Amgen to $457 From $427, Maintains Overweight Rating	MT
19/08	Argus Research Adjusts Amgen Price Target to $460 From $375, Maintains Buy Rating	MT
19/08	Morgan Stanley Adjusts Price Target on Amgen to $362 From $351, Keeps Equalweight Rating	MT
18/08	Mizuho Adjusts Price Target on Amgen to $352 From $303, Maintains Neutral Rating	MT
18/08	Cantor Fitzgerald Adjusts Price Target on Amgen to $400 From $350, Maintains Neutral Rating	MT
18/08	Mizuho Securities Adjusts Amgen Price Target to $352 From $303	MT
13/08	Daiwa Securities Adjusts Price Target on Amgen to $430 From $390, Keeps Outperform Rating	MT
13/08	Barclays Adjusts Price Target on Amgen to $380 From $360, Maintains Equalweight Rating	MT
10/08	HSBC Adjusts Price Target on Amgen to $445 From $425, Keeps Buy Rating	MT
07/08	Citigroup Adjusts Price Target on Amgen to $405 From $345, Maintains Neutral Rating	MT
07/08	Rothschild & Co Redburn Adjusts Amgen Price Target to $235 From $220, Maintains Sell Rating	MT
05/08	Bernstein Adjusts Price Target on Amgen to $345 From $335, Maintains Market Perform Rating	MT
05/08	UBS Adjusts Price Target on Amgen to $440 From $420, Maintains Buy Rating	MT
05/08	JPMorgan Adjusts Price Target on Amgen to $350 From $300, Maintains Neutral Rating	MT
05/08	Wells Fargo Adjusts Price Target on Amgen to $400 From $390, Maintains Equalweight Rating	MT
05/08	Leerink Partners Adjusts Price Target on Amgen to $395 From $355, Maintains Market Perform Rating	MT
05/08	TD Cowen Adjusts Price Target on Amgen to $452 From $420, Maintains Buy Rating	MT
05/08	Goldman Sachs Adjusts Price Target on Amgen to $450 From $427, Maintains Buy Rating	MT
05/08	BMO Capital Adjusts Price Target on Amgen to $450 From $400, Maintains Outperform Rating	MT
05/08	Scotiabank Adjusts Price Target on Amgen to $450 From $385, Maintains Sector Outperform Rating	MT
05/08	Canaccord Genuity Adjusts Price Target on Amgen to $384 From $366, Maintains Hold Rating	MT
05/08	Baird Adjusts Price Target on Amgen to $230 From $215, Maintains Underperform Rating	MT
05/08	Oppenheimer Adjusts Price Target on Amgen to $450 From $400, Maintains Outperform Rating	MT
05/08	BofA Adjusts Price Target on Amgen to $317 From $312	MT
05/08	RBC Capital Adjusts Price Target on Amgen to $400 From $370, Maintains Outperform Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+10.56%
	JOHNSON & JOHNSON					+0.93%
	ABBVIE INC.					+5.21%
	ROCHE HOLDING AG					+0.54%
	NOVARTIS AG					-2.25%
	ASTRAZENECA PLC					+27.85%
	AMGEN INC.					-11.78%
	NOVO NORDISK A/S					+1.92%
	GILEAD SCIENCES, INC.					+6.29%
	Average					+4.36%
	Weighted average by Cap.					+5.28%